Clinical Scorecard: Multi-omics Approach Identifies HLA-DPA1/DPB1 Downregulation as a Factor in Macrophage Immune-Metabolic Dysregulation in Children with Asthma
At a Glance
Category
Detail
Condition
Pediatric Asthma (PA)
Key Mechanisms
Dysregulated macrophage heterogeneity and immune-metabolic crosstalk
Target Population
Children with asthma
Care Setting
Clinical and research settings
Key Highlights
HLA-DPA1 and HLA-DPB1 are downregulated in Pediatric Asthma.
Downregulation correlates with impaired antigen presentation and metabolic dysfunction.
Macrophage heterogeneity plays a significant role in immune regulation.
IL-13 stimulation confirms reduced expression of HLA-DPA1/DPB1.
Cell communication analysis identifies key signaling pathways in asthma.
Guideline-Based Recommendations
Diagnosis
Utilize differential expression analysis of immune checkpoint-related genes.
Management
Consider targeting HLA-DPA1/DPB1 pathways for potential therapeutic strategies.
Monitoring & Follow-up
Assess immune-metabolic markers in pediatric asthma patients.
Risks
Increased risk of refractory asthma due to immune dysregulation.
Patient & Prescribing Data
Children aged 0-14 with asthma.
Existing therapies may have limited efficacy in some patients.
Clinical Best Practices
Incorporate multi-omics approaches to understand asthma pathogenesis.
Evaluate immune checkpoint roles in asthma for personalized treatment.
